Moody's places Select Medical's ratings on review for downgrade

Moody's places Select Medical's ratings on review for downgrade

Moody’s Investors Service has placed Select Medical Corp’s credit ratings on review for a potential downgrade, citing persistent cost pressures and evolving risks within the healthcare sector. The move aligns with broader industry challenges highlighted in Moody’s recent analysis, including rising medical costs, inflationary pressures, and regulatory uncertainties. Analysts noted that elevated expenses—driven by prescription drug spending, behavioral health utilization, and commercial market dynamics—continue to strain insurers and healthcare providers, with reimbursement rates in Medicare Advantage (MA) and Medicaid programs lagging behind medical cost growth.

The review follows Moody’s broader downgrade of the insurance industry’s credit outlook to negative, reflecting concerns that premium increases may not fully offset rising spending. For Select Medical, the review likely considers its exposure to these systemic trends, including competitive pressures in provider contract negotiations and potential regulatory shifts, such as proposed reforms targeting pharmacy benefit managers as detailed in Moody’s analysis. While enrollment growth in MA and individual markets offers some near-term stability, analysts emphasized that sustained cost moderation and a favorable regulatory environment would be critical to restoring a stable outlook.

Moody’s also highlighted uncertainties surrounding potential changes to Medicare and Medicaid policies under a future Trump administration, which could further complicate financial planning for healthcare entities according to Moody’s outlook. The rating agency will reassess Select Medical’s creditworthiness in light of these factors, with a decision expected as industry dynamics evolve.